X
<

Pfizer’s 2017 Performance in Review

PART:
1 2 3 4 5 6 7 8 9 10 11 12
Part 5
Pfizer’s 2017 Performance in Review PART 5 OF 12

How Did Pfizer’s Viagra and Lyrica Perform in 2017?

PFE’s Viagra revenue trends

In fiscal 2017, Pfizer’s (PFE) Viagra reported revenues of $1.2 billion, which represented a ~23% decline on a YoY (year-over-year) basis. In 2017, in the US and outside the US (international markets), Viagra generated revenues of $789 million and $416 million, respectively.

In 2017, in international markets, Viagra sales remained flat, compared with 2016 while, Viagra witnessed a 31% decline on a YoY basis in the US. In 4Q17, Viagra generated revenues of $209 million, which represents a ~45% rise on a YoY basis and a 32% rise on a quarter-over-quarter basis.

How Did Pfizer’s Viagra and Lyrica Perform in 2017?

Interested in LLY? Don't miss the next report.

Receive e-mail alerts for new research on LLY

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

In 4Q17, in the US and in international markets, Viagra reported revenues of $102 million and $107 million, respectively, compared with $275 million and $106 million in 4Q16.

In the marketplace, Viagra faces stiff competition from Eli Lilly’s (LLY) Cialis, Bayer’s (BAYZF) Levitra, and Mist Pharmaceuticals’ Stendra.

Lyrica revenue trends

In fiscal 2017, Lyrica reported revenues of $5.1 billion, which reflected a ~2% rise on a YoY basis. In 2017, in the US and in international markets, Lyrica reported revenues of $3.4 billion and $1.6 billion, respectively, compared with $3.1 billion and $1.8 billion in 2016, reflecting ~10% growth and a ~12% decline, respectively, on a YoY basis.

In 4Q17, Lyrica reported revenues of $1.25 billion, which represents a ~2% rise on a YoY basis and 2% decline on a YoY basis. In 4Q17, in the US and in international markets, Lyrica reported revenues of $861 million and $393 million, respectively, compared with $782 million and $454 million in 4Q16.

Lyrica is used for the treatment of postherpetic neuralgia, partial-onset seizures, and fibromyalgia. Lyrica is also used for the treatment of neuropathic pain associated with diabetic peripheral neuropathy and spinal cord injury.

Some of Lyrica’s competitor drugs in the marketplace used for the treatment of fibromyalgia include Eli Lilly’s (LLY) Cymbalta and Allergan’s (AGN) Savella.

In the next part of this series, we’ll assess the performance of Pfizer’s inflammation and immunization portfolios in 4Q17 and 2017.

X

Please select a profession that best describes you: